Program 02
Microinvasive DCIS Biology
Which genomic and biological mechanisms allow a pre-invasive lesion to progress to invasiveness?
Why This Program
The premise behind Program 02.
Ductal carcinoma in situ (DCIS) makes up a significant portion of early breast cancer. Its spectrum ranges from in situ (Tis/DCIS) to pre-microinvasive stages (T0) and early invasive lesions (T1), including microinvasion ≤1 mm.
Despite its prevalence, predicting the transition from DCIS to invasive disease remains challenging. Current classification primarily relies on histopathology and imaging—with limited consideration of cellular, genomic, metabolic, and microenvironmental factors—often resulting in overtreatment of benign lesions and underestimation of risk in high-risk cases, especially among young women.
What We Mean
Defining microinvasive dcis biology.
We define microinvasive DCIS biology as the integrated genomic, cellular, and microenvironmental processes that precede and enable early invasion—before clinically significant tumor expansion.
- Genomic and cellular programs — Early clonal heterogeneity, copy-number alterations, and evolutionary trajectories interacting with metabolic stress, mitochondrial signaling, and epithelial plasticity to shape progression potential.
- Tissue microenvironment and regulation — Immune surveillance and escape, alongside stromal remodeling and extracellular matrix dynamics, regulating whether early lesions remain contained or progress toward invasion.
- Continuum of early disease states — Spanning Tis (DCIS), through biologically primed pre-microinvasive states (T0), to T1 microinvasive disease—marking the earliest breach of the basement membrane.
Rather than viewing DCIS as a static entity, this program treats it as a dynamic, evolving system in which invasion arises from the interplay of genomic evolution and tissue-ecosystem disruption.